RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Non-Small Cell Lung Cancer with an EGFR Mutation (Faculty Presentations)
Released November 2020

Featuring slide presentations and related discussion from Drs Roy S Herbst, Suresh S Ramalingam and Helena Yu. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).


    • Recognize the spectrum of oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how they may predict potential response or lack thereof to EGFR-directed therapy.
    • Appreciate emerging Phase III findings supporting the use of adjuvant osimertinib after complete resection for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the potential effect of this information on clinical practice.
    • Evaluate available clinical trial findings supporting the use of osimertinib as first-line therapy for patients with advanced NSCLC with EGFR mutations, and consider the effect of this information on current and future clinical practice.
    • Comprehend the mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and discern how available and investigational therapies can be optimally employed in protocol and nonresearch care of patients with progressive NSCLC with EGFR mutations.
    • Formulate an optimal approach to the clinical care of patients with NSCLC with EGFR mutations and CNS metastases, considering the implications of symptomatology, number of lesions and other factors.
    • Consider available research data to determine how to sequence immune checkpoint inhibitors in the long-term care of patients with metastatic NSCLC and an EGFR activating mutation.
    • Understand the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with NSCLC and EGFR mutations.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/IASLC20/Presentations/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine
    Professor of Pharmacology
    Chief of Medical Oncology
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee: BioNTech AG, Bolt Biotherapeutics, Cybrexa Therapeutics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Biodesix Inc, BioNTech AG, Bolt Biotherapeutics, Bristol-Myers Squibb Company, Cybrexa Therapeutics, eFFECTOR Therapeutics Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab, Halozyme Inc, Heat Biologics Inc, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mirati Therapeutics, Nektar, NextCure, Novartis, Oncternal Therapeutics, Pfizer Inc, Sanofi Genzyme, Seagen Inc, Spectrum Pharmaceuticals Inc, Symphogen A/S, Takeda Oncology, Tesaro, A GSK Company, Tocagen, WindMIL Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly, Merck; Data and Safety Monitoring Board/Committee: Novartis; Nonexecutive/Independent Board Member: Junshi Biosciences.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Roberto C Goizueta Chair for Cancer Research
    Director, Division of Medical Oncology
    Deputy Director, Winship Cancer Institute
    Emory University School of Medicine
    Atlanta, Georgia

    Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck, Takeda Oncology; Contracted Research: Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck, Takeda Oncology, Tesaro, A GSK Company.

    Helena Yu, MD
    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Lilly, Novartis, Pfizer Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Release date: November 2020
    Expiration date: November 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):